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Abstract 
   
Management of rheumatoid arthritis (RA) in many Latin-American countries is 
impaired by fragmentation and scarce healthcare provision, resulting in obstacles 
to access, diagnosis, and treatment, and consequently in poor health outcomes. 
The aim of this study is to propose a comprehensive care program as a model to 
provide healthcare to RA patients receiving synthetic DMARDs in a Colombian 
setting by describing the model and its results. Health outcomes were 
prospectively collected in all patients entering the program. By protocol, patients 
are followed up during 24 months using a treat-to-target strategy with a patient-
centered care (PCC) model, meaning that a patient should be seen by 
rheumatologist, physical and occupational therapist, physiatrist, nutritionist and 
psychologist, at least three times a year according to disease activity by DAS28. 
Otherwise, patients receive standard therapy. The incidence of remission and low 
disease activity (LDA) was calculated by periods of follow-up. A total of 968 
patients entered the program from January 2015 to December 2016; 80.2% were 
women. At baseline, 41% of patients were in remission, 17% in LDA and 42% in 
MDS/SDA. At 24 months of follow-up, 66% were in remission, 18% in LDA and 
only 16% in MDS/SDA. Regarding DAS28, the mean at the beginning of the time 
analysis was 3.1 (SD 1.0) and after 24 months it was 2.4 (SD 0.7), showing a 
statistically significant improvement (p < 0.001). In all patients, the reduction of 
disease activity was 65% (95% CI, 58–71). Patients entering the PCC program 
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